Imagion Biosystems has announced a letter to shareholders regarding the 28 October 2019 announcement of a renounceable pro-rata offer.
Read the letter to shareholders.
Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority